Showing 3021-3030 of 3415 results for "".
- ASDS Survey Highlights Teledermatology Boom, Staffing Challenges, and Other Ways COVID-19 Upended Practicehttps://practicaldermatology.com/news/asds-survey-sites-teledermatology-boom-staffing-challenges-and-other-ways-pandemic-upended-practice/2461070/From dramatic upticks in the use of teledermatology to staffing challenges and delays in procedures, the ongoing COVID-19 pandemic continues to affect dermatology practices and patients, according to a
- Merz Aesthetics Launches Radiesse (+) as First and Only Aesthetic Injectable to Improve Moderate to Severe Loss of Jawline Contourhttps://practicaldermatology.com/news/merz-aesthetics-launches-radiesse-as-first-and-only-aesthetic-injectable-to-improve-moderate-to-severe-loss-of-jawline-contour/2461062/Merz Aesthetics is launching Radiesse (+) Lidocaine for jawline contouring in adults over the age of 21. Radiesse (+) is the first and only U.S. Food and Drug Administration (FDA)-approved injectable treatment for jawline contour improvement. The FDA approved the supplemental
- FDA Approves Pfizer's Cibinqo for Moderate-to-Severe AD in Adultshttps://practicaldermatology.com/news/fda-approves-pfizers-cibinqo-for-moderate-to-severe-ad-in-adults/2461037/Pfizer's Cibinqo® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, is now FDA approved for the treatment of adults with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including bi
- FDA Accepts Arcutis Biotherapeutics’ NDA for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-arcutis-biotherapeutics-nda-for-roflumilast-cream-for-adults-and-adolescents-with-plaque-psoriasis/2461018/The FDA accepted Arcutis Biotherapeutics’ new drug application (NDA) for roflumilast cream for the treatment of psoriasis in adults and adolescents. The FDA assigned the application a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2022. “With the FDA c
- Rinvoq Scores FDA Nod for Active Psoriatic Arthritishttps://practicaldermatology.com/news/rinvoq-scores-us-fda-nod-for-active-psoriatic-arthritis/2461012/The U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. "The efficacy
- FDA Accepts NDA for Boehringer Ingelheim’s Spesolimab for GPPhttps://practicaldermatology.com/news/fda-accepts-nda-for-boehringer-ingelheims-spesolimab-for-gpp/2461010/FDA has accepted a Biologics License Application (BLA) and granted Priority Review for Boehringer Ingelheim’s spesolimab for the treatment of generalized pustular psoriasis (GPP) flares. The FDA has granted spesolimab Orphan Drug Designation for the treatment of GPP, and Bre
- FDA Accepts sNDA for Incyte's Opzelura for Vitiligohttps://practicaldermatology.com/news/fda-accepts-snda-for-incytes-opzelura-for-vitiligo/2461009/FDA has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib cream 1.5% (Opzelura™) a topical JAK inhibitor from Incyte, as a potential treatment for adolescents and adults with vitiligo. The sNDA is supported by data from the Phase 3 TRuE-V cl
- FDA Clears New Lifting Indications for Sofwavehttps://practicaldermatology.com/news/new-indications-for-sofwave/2460996/Sofwave is now U.S. Food and Drug Administration (FDA)-cleared for lifting the eyebrow and lifting lax submental tissue and neck tissue in people aged 22 or older. In addition, the Sofwave system featuring the Company's proprietary Superb TM (Synchronous Ultrasound Parallel Be
- FDA Fast Tracks Union Therapeutics' AD Candidatehttps://practicaldermatology.com/news/fda-fast-tracks-union-therapeutics-ad-candidate/2460978/The US Food and Drug Administration (FDA) has granted Fast Track designation to Union Therapeutics’ oral orismilast for the treatment of moderate to severe atopic dermatitis (AD). Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory properti
- Castle Creek Biosciences Awarded FDA Orphan Products Development Grant to Support Phase 3 Study of FCX-007 Investigational Gene Therapy for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/castle-creek-biosciences-awarded-fda-orphan-products-development-grant-to-support-phase-3-study-of-fcx-007-investigational-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa/2460966/The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development awarded Castle Creek Biosciences a $1.825 million research grant to support the Phase 3 development program of the investigational gene therapy FCX-007 for treatment of recessive dystrophic epide